{"entity":{"id":"todd-golub","kind":"person","name":"Todd R. Golub","aka":[],"tldr":"Showed that gene expression could classify cancers, then built the Broad into the engine of cancer genomics.","summary":"Todd R. Golub is Director of the Broad Institute of MIT and Harvard and Charles A. Dana Investigator at Dana-Farber. He is known for showing that gene expression could classify cancers, with a 1999 leukaemia classification paper that launched expression-based cancer taxonomy, and for building the Broad into the engine of cancer genomics as founding director of its cancer programme. His selected papers report the molecular classification of cancer by gene expression monitoring and the discovery of anticancer potential in non-oncology drugs through systematic viability profiling. His laboratory created the PRISM pooled cell-line screening platform behind DepMap, and he has been Broad director since 2020.","asOf":"2026-09-08","links":[{"label":"Broad bio","url":"https://www.broadinstitute.org/bios/todd-r-golub"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Golub%20TR%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["aml","all-leukemia"],"sections":[],"technologies":["crispr-screens","rna-seq"],"targets":[],"drugs":[],"companies":[],"institutions":["broad-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-cancer"],"dependsOn":[],"notes":[],"role":"Director, Broad Institute; Charles A. Dana Investigator, Dana-Farber","institutionId":"broad-institute","specialisms":["Cancer genomics","Functional genomics","PRISM drug screening","Paediatric leukaemia"],"profiles":[{"label":"Broad bio","url":"https://www.broadinstitute.org/bios/todd-r-golub"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Golub%20TR%5BAuthor%5D"}],"papers":[{"title":"Molecular classification of cancer: class discovery and class prediction by gene expression monitoring","journal":"Science","year":1999,"url":"https://doi.org/10.1126/science.286.5439.531","doi":"10.1126/science.286.5439.531"},{"title":"Discovering the anticancer potential of non-oncology drugs by systematic viability profiling","journal":"Nature Cancer","year":2020,"url":"https://doi.org/10.1038/s43018-019-0018-6","doi":"10.1038/s43018-019-0018-6"}]},"route":"/people/todd-golub/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"technology":[{"id":"crispr-screens","kind":"technology","name":"CRISPR functional genomics","route":"/technologies/crispr-screens/"},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"}],"institution":[{"id":"broad-institute","kind":"institution","name":"Broad Institute of MIT and Harvard","route":"/institutions/broad-institute/"}],"journal":[{"id":"nature-cancer","kind":"journal","name":"Nature Cancer","route":"/journals/nature-cancer/"}]}}